Asthma

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

Retrieved on: 
Friday, January 14, 2022 - 7:30pm

The Kuihuapan products are produced according to the four processing specifications of Chinese Pharmacopoeia (2020 Edition) No.

Key Points: 
  • The Kuihuapan products are produced according to the four processing specifications of Chinese Pharmacopoeia (2020 Edition) No.
  • As of December 31, 2021, there are 12 batches of Luxuejin Directly-Oral TCMP products produced by lyophilizationprocess.
  • With the continuous increased market demand for Luxuejin, we will work to increase our production capacity and we believe the output value will grow rapidly.
  • "The developed R&D and production of Advanced TCMP products will greatly help us make continuous efforts in leading the R&D of Advanced TCMP and pursuing higher quality products.

Opus Inspection and Envirotest Help Tennessee Achieve Federal Air Quality Standards

Retrieved on: 
Thursday, January 13, 2022 - 2:00pm

EAST GRANBY, Conn., Jan. 13, 2022 /PRNewswire/ -- Since 1985, Opus Inspection with our subsidiary Envirotest has operated the vehicle emission testing programs in the Tennessee counties of Davidson, Hamilton, Rutherford, Sumner, Williamson, and Wilson.With the programs coming to an end on February 4 in Davidson County and January 14 elsewhere, we want to celebrate the success of these programs with the citizens of Tennessee and our partners at Metro Public Health Department and Tennessee Department of Environment & Conservation.Together, we have reached attainment of the federal air quality standards for the Middle Tennessee region, which was no easy feat.Most other states with large metropolitan areas have a long way to go before they can match Tennessee's achievement.

Key Points: 
  • EAST GRANBY, Conn., Jan. 13, 2022 /PRNewswire/ -- Since 1985, Opus Inspection with our subsidiary Envirotest has operated the vehicle emission testing programs in the Tennessee counties of Davidson, Hamilton, Rutherford, Sumner, Williamson, and Wilson.With the programs coming to an end on February 4 in Davidson County and January 14 elsewhere, we want to celebrate the success of these programs with the citizens of Tennessee and our partners at Metro Public Health Department and Tennessee Department of Environment & Conservation.Together, we have reached attainment of the federal air quality standards for the Middle Tennessee region, which was no easy feat.Most other states with large metropolitan areas have a long way to go before they can match Tennessee's achievement.
  • This accomplishment means that tens of thousands of Tennesseans have benefitted from a better quality of life, especially those with asthma and other vulnerable groups including children and the elderly.The inspection program in middle Tennessee has been reducing emissions of carbon monoxide (CO) by more than 10,000 tons per year, oxides of nitrogen (NOx) by more than 500 tons per year and volatile organic compounds (VOC) by more than 600 tons per year.And, by attaining the federal clean air standards, the State fostered a more sustainable business environment for Tennessee employers.
  • We encourage Tennessee motorists to keep up the good work.Continue to maintain your cars and trucks, and please don't ignore the check-engine light.
  • Mr. Andy McIntosh, CEO of Envirotest said, "Our vision and mission is to make the world a cleaner and safer place.As vehicle emission testing in Tennessee is ending, we want to thank Tennessee motorists in Middle-Tennessee and Chattanooga, and the hard-working Tennessee employees of Opus/Envirotest who strived to provide an efficient and quality service to the public.We'd also like to thank our partners in state and local government and the auto technicians who have repaired emission systems so that air pollution has been reduced and Tennesseans can breathe easier."

TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

Retrieved on: 
Thursday, January 13, 2022 - 12:00pm

The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.

Key Points: 
  • The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

Retrieved on: 
Thursday, January 13, 2022 - 12:00pm

With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.

Key Points: 
  • With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.

Pulmonary Drug Delivery Systems Market Forecasts to 2026: A US$56.942 Billion Market by 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 13, 2022 - 10:07am

The "Pulmonary Drug Delivery Systems Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary Drug Delivery Systems Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The pulmonary drug delivery systems market is projected to grow at a CAGR of 4.83% to reach US$56.942 billion by 2026, from US$40.929 billion in 2019.
  • The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period.
  • The increase in the geriatric population across the globe is expected to drive the market growth of pulmonary drug delivery systems.

Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions Selected to Dispense TEZSPIRE™ (tezepelumab) for the Treatment of Severe Asthma

Retrieved on: 
Wednesday, January 12, 2022 - 8:25pm

Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions announce today that they are now dispensing TEZSPIRE (tezepelumab), the first biologic to significantly reduce exacerbations in broad populations of patients with severe, uncontrolled asthma.

Key Points: 
  • Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions announce today that they are now dispensing TEZSPIRE (tezepelumab), the first biologic to significantly reduce exacerbations in broad populations of patients with severe, uncontrolled asthma.
  • Through this partnership, Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions' high touch, whole-health service model will support asthma patients and providers throughout the country, including allergists, immunologists and pulmonologists.
  • For more information about Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions services, call (888) 370-1724 or visit www.amberpharmacy.com .
  • Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.

First-Of-Its-Kind Project To Use Private-Sector Funding to Reduce Asthma for NYC Medicaid Recipients

Retrieved on: 
Wednesday, January 12, 2022 - 4:21pm

"This project captures the vision that funding health-based housing interventions to lower the incidence of asthma is critical to addressing the social determinants of health and equity.

Key Points: 
  • "This project captures the vision that funding health-based housing interventions to lower the incidence of asthma is critical to addressing the social determinants of health and equity.
  • The project aims to reduce serious asthma episodes among 850 children and adults who have chronic asthma.
  • Helping people with asthma manage these issues earlier will reduce costs by preventing avoidable emergency department visits and hospitalizations.
  • Estimates indicate that the project will result in $6.5 million in healthcare savings which more than compensates for the initial investment.

GreenPower Announces Plan to Manufacture Zero-Emission, All Electric School Buses in West Virginia

Retrieved on: 
Wednesday, January 12, 2022 - 3:00pm

GreenPower has entered into a lease/purchase agreement with the state of West Virginia to acquire properties located in South Charleston, West Virginia totaling 9.5 acres and an 80,000 square foot building.

Key Points: 
  • GreenPower has entered into a lease/purchase agreement with the state of West Virginia to acquire properties located in South Charleston, West Virginia totaling 9.5 acres and an 80,000 square foot building.
  • "The state has agreed to facilitate the purchase of a minimum of $15 million in zero-emission GreenPower school buses produced at the facility.
  • "The first purpose-built, all electric school buses that are produced in South Charleston will directly benefit the health and well-being of the families in West Virginia," Riley said.
  • The $15 million investment by West Virginia will leverage funds from other incentive programs to substantially increase the number of GreenPower school buses on the roads in West Virginia."

LifeMD Expands Patient Offerings by Acquiring Leading Allergy Telehealth Platform

Retrieved on: 
Wednesday, January 12, 2022 - 1:00pm

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced it has acquired Cleared, a rapidly growing nationwide allergy telehealth platform.

Key Points: 
  • Acquisition of Cleared Further Diversifies LifeMDs Telehealth Offerings to Encompass Allergy, Asthma, and Immunology
    NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced it has acquired Cleared, a rapidly growing nationwide allergy telehealth platform.
  • Cleared (www.getcleared.com) is a telehealth brand that provides personalized treatments for allergy, asthma, and immunology.
  • These partnerships allow Cleared to offer patients lower-priced allergy treatments by leveraging the efficiencies of a vertically integrated supply chain.
  • LifeMD, Inc. is a rapidly growing direct-to-patient telehealth company that offers cash-pay virtual medical care across all 50 states.

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®

Retrieved on: 
Tuesday, January 11, 2022 - 1:00pm

The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.

Key Points: 
  • The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.
  • Symptoms were assessed approximately 15 minutes prior to chamber entry, and every 5 minutes beginning 5 minutes after chamber entry.
  • Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis.
  • Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.